Literature DB >> 12086949

Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle.

Svetlana E Nikoulina1, Theodore P Ciaraldi, Sunder Mudaliar, Leslie Carter, Kirk Johnson, Robert R Henry.   

Abstract

Glycogen synthase kinase (GSK)-3 has been implicated in the regulation of multiple cellular physiological processes in skeletal muscle. Selective cell-permeable reversible inhibitors (INHs) of GSK-3 (CT98014 and CHIR98023 [Chiron, Emeryville, CA] and LiCl) were used to evaluate the role of GSK-3 in controlling glucose metabolism. Acute treatment (30 min) of cultured human skeletal muscle cells with either INH resulted in a dose-dependent activation of glycogen synthase (GS) with a maximally effective concentration of approximately 2 micromol/l. The maximal acute effect of either INH on GS (103 +/- 25% stimulation over basal) was greater than the maximal insulin response (48 +/- 9%, P < 0.05 vs. INH); LiCl was as effective as insulin. The GSK-3 inhibitor effect, like that of insulin, was on the activation state (fractional velocity [FV]) of GS. Cotreatment of muscle cells with submaximal doses of INH and insulin resulted in an additive effect on GS FV (103 +/- 10% stimulation, P < 0.05 vs. either agent alone). Glucose incorporation into glycogen was also acutely stimulated by INH. While prolonged (6-24 h) insulin exposure led to desensitization of GS, INH continued to activate GS FV for at least 24 h. Insulin and LiCl acutely activated glucose uptake, whereas INH stimulation of glucose uptake required more prolonged exposure, starting at 6 h and continuing to 24 h. Chronic (4-day) treatment with INH increased both basal (154 +/- 32% of control) and insulin-stimulated (219 +/- 74%) glucose uptake. Upregulation of uptake activity occurred without any change in total cellular GLUT1 or GLUT4 protein content. Yet the same chronic treatment resulted in a 65 +/- 6% decrease in GSK-3 protein and a parallel decrease (61 +/- 11%) in GSK-3 total activity. Together with the INH-induced increase in insulin-stimulated glucose uptake, there was an approximately 3.5-fold increase (P < 0.05) in insulin receptor substrate (IRS)-1 protein abundance. Despite upregulation of IRS-1, maximal insulin stimulation of Akt phosphorylation was unaltered by INH treatment. The results suggest that selective inhibition of GSK-3 has an impact on both GS and glucose uptake, including effects on insulin action, using mechanisms that differ from and are additive to those of insulin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12086949     DOI: 10.2337/diabetes.51.7.2190

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  51 in total

Review 1.  GSK3beta: role in therapeutic landscape and development of modulators.

Authors:  S Phukan; V S Babu; A Kannoji; R Hariharan; V N Balaji
Journal:  Br J Pharmacol       Date:  2010-03-19       Impact factor: 8.739

Review 2.  Targeting glycogen synthase kinase-3 (GSK-3) in the treatment of Type 2 diabetes.

Authors:  Katrina MacAulay; James R Woodgett
Journal:  Expert Opin Ther Targets       Date:  2008-10       Impact factor: 6.902

3.  Short-term in vitro inhibition of glycogen synthase kinase 3 potentiates insulin signaling in type I skeletal muscle of Zucker Diabetic Fatty rats.

Authors:  Erik J Henriksen; Mary K Teachey
Journal:  Metabolism       Date:  2007-07       Impact factor: 8.694

Review 4.  Physiological roles of glycogen synthase kinase-3: potential as a therapeutic target for diabetes and other disorders.

Authors:  J R Woodgett
Journal:  Curr Drug Targets Immune Endocr Metabol Disord       Date:  2003-12

5.  Insulin receptor substrate 2-mediated phosphatidylinositol 3-kinase signaling selectively inhibits glycogen synthase kinase 3β to regulate aerobic glycolysis.

Authors:  Justine Landis; Leslie M Shaw
Journal:  J Biol Chem       Date:  2014-05-08       Impact factor: 5.157

6.  Glucocorticoid-induced insulin resistance in skeletal muscles: defects in insulin signalling and the effects of a selective glycogen synthase kinase-3 inhibitor.

Authors:  J Ruzzin; A S Wagman; J Jensen
Journal:  Diabetologia       Date:  2005-08-03       Impact factor: 10.122

7.  Hypothalamic glycogen synthase kinase 3β has a central role in the regulation of food intake and glucose metabolism.

Authors:  Jonas Benzler; Goutham K Ganjam; Manon Krüger; Olaf Pinkenburg; Maria Kutschke; Sigrid Stöhr; Juliane Steger; Christiane E Koch; Rebecca Ölkrug; Michael W Schwartz; Peter R Shepherd; David R Grattan; Alexander Tups
Journal:  Biochem J       Date:  2012-10-01       Impact factor: 3.857

8.  Shilianhua extract inhibits GSK-3beta and promotes glucose metabolism.

Authors:  Jun Yin; Aamir Zuberi; Zhanguo Gao; Dong Liu; Zhijun Liu; Jianping Ye
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-04-07       Impact factor: 4.310

9.  Tissue-specific role of glycogen synthase kinase 3beta in glucose homeostasis and insulin action.

Authors:  Satish Patel; Bradley W Doble; Katrina MacAulay; Elaine M Sinclair; Daniel J Drucker; James R Woodgett
Journal:  Mol Cell Biol       Date:  2008-08-11       Impact factor: 4.272

10.  A sugar-inducible protein kinase, VvSK1, regulates hexose transport and sugar accumulation in grapevine cells.

Authors:  Fatma Lecourieux; David Lecourieux; Céline Vignault; Serge Delrot
Journal:  Plant Physiol       Date:  2009-11-18       Impact factor: 8.340

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.